文献速递脑血管病

NAVIGATE-ESUS 试验中不明来源栓塞性卒中的潜在栓塞来源与结局

Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
PubMed 文献 · Stroke · 2020-04-16

本研究在 NAVIGATE-ESUS 试验的 7213 例 ESUS 患者中分析各潜在栓塞来源(PES)的分布及利伐沙班与阿司匹林的疗效差异。各 PES 下两治疗组复发缺血性卒中风险相似,仅心脏瓣膜病者利伐沙班组略高(HR 1.8,95%CI 1.0-3.0)。

要点

  • 各 PES 亚组中利伐沙班与阿司匹林的卒中复发风险总体相似。
  • 心脏瓣膜病患者利伐沙班相关卒中复发风险边缘性升高。

核心结论

  • ESUS 患者中大部分存在多种 PES,可能解释 NAVIGATE-ESUS 的中性结果。
  • 利伐沙班与阿司匹林组复发风险在各 PES 谱系中相似。

研究设计与样本

  • NAVIGATE-ESUS 试验的事后分析,纳入 7213 例 ESUS 患者,38% 为女性,平均年龄 67 岁,中位随访 11 个月。
  • 评估每位患者各 PES 的存在与否,并分析不同 PES 数量下的治疗效应与事件风险。

主要发现

  • 最常见 PES 为心房心脏病(37%)、左心室疾病(36%)、动脉粥样硬化(29%)。
  • 除心脏瓣膜病外,各 PES 下利伐沙班与阿司匹林组复发缺血性卒中风险相似;心脏瓣膜病者利伐沙班组风险边缘性升高(HR 1.8,95%CI 1.0-3.0)。
  • 各 PES 下两治疗组全因死亡风险相似;心肌梗死与心血管死亡事件过少无法有意义的评估。
  • PES 数量增加与卒中复发及全因死亡风险升高无关,且按 PES 数量分层后两治疗组结局无差异。

临床怎么用

  • 对 ESUS 患者应系统评估多种潜在栓塞来源,而非仅针对单一病因。
  • 在合并心脏瓣膜病的 ESUS 患者中选用利伐沙班需谨慎权衡。

局限性

  • 为试验事后分析,各 PES 亚组事件数有限,尤其心肌梗死与心血管死亡过少。
  • 心脏瓣膜病亚组结果仅为边缘性关联,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Emboli in embolic stroke of undetermined source (ESUS) may originate from various potential embolic sources (PES), some of which may respond better to anticoagulation, whereas others to antiplatelets. We analyzed whether rivaroxaban is associated with reduction of recurrent stroke compared with aspirin in patients with ESUS across different PES and by number of PES. Methods- We assessed the presence/absence of each PES (atrial cardiopathy, atrial fibrillation, arterial atherosclerosis, left ventricular dysfunction, cardiac valvulopathy, patent foramen ovale, cancer) in NAVIGATE-ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) participants. Prevalence of each PES, as well as treatment effect and risk of event for each PES were determined. Results by number of PES were also determined. The outcomes were ischemic stroke, all-cause mortality, cardiovascular mortality, and myocardial infarction. Results- In 7213 patients (38% women, mean age 67years) followed for a median of 11 months, the 3 most prevalent PES were atrial cardiopathy (37%), left ventricular disease (36%), and arterial atherosclerosis (29%). Forty-one percent of all patients had multiple PES, with 15% having ≥3 PES. None or a single PES was present in 23% and 36%, respectively. Recurrent ischemic stroke risk was similar for rivaroxaban- and aspirin-assigned patients for each PES, except for those with cardiac valvular disease which was marginally higher in rivaroxaban-assigned patients (hazard ratio, 1.8 [95% CI, 1.0-3.0]). All-cause mortality risks were similar across treatment groups for each PES while too few myocardial infarctions and cardiovascular deaths occurred for meaningful assessment. Increasing number of PES was not associated with increased stroke recurrence nor all-cause mortality, and outcomes did not vary between rivaroxaban- and aspirin-assigned patients by number of PES. Conclusions- A large proportion of patients with ESUS had multiple PES which could explain the neutral results of NAVIGATE-ESUS. Recurrence rates between rivaroxaban- and aspirin-assigned patients were similar across the spectrum of PES. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ntaios G, Pearce LA, Veltkamp R, et al. Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. Stroke. 2020. PMID: 32295509. doi:10.1161/STROKEAHA.119.028669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。